BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 8525524)

  • 1. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
    Remberger M; Ringdén O
    Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation.
    Foley R; Couban S; Walker I; Greene K; Chen CS; Messner H; Gauldie J
    Bone Marrow Transplant; 1998 Apr; 21(8):769-73. PubMed ID: 9603399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
    Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
    Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease.
    Miyamoto T; Akashi K; Hayashi S; Gondo H; Murakawa M; Tanimoto K; Harada M; Niho Y
    Bone Marrow Transplant; 1996 Feb; 17(2):185-90. PubMed ID: 8640164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation.
    Ferrà C; de Sanjosé S; Gallardo D; Berlanga JJ; Rueda F; Marìn D; de la Banda E; Ancìn I; Peris J; Garcìa J; Grañena A
    Haematologica; 1998 Dec; 83(12):1082-7. PubMed ID: 9949625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD.
    Grimm J; Zeller W; Zander AR
    Bone Marrow Transplant; 1998 Jan; 21(1):29-32. PubMed ID: 9486491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease.
    Imamura M; Hashino S; Kobayashi H; Kubayashi S; Hirano S; Minagawa T; Tanaka J; Fujii Y; Kobayashi M; Kasai M
    Bone Marrow Transplant; 1994 Jun; 13(6):745-51. PubMed ID: 7920309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble interferon-gamma receptor and interferon-gamma in patients undergoing allogeneic bone marrow transplantation for hematological malignancies.
    Toren A; Barak V; Novick D; Nagler A
    Cytokines Cell Mol Ther; 1997 Sep; 3(3):153-8. PubMed ID: 9426973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.
    Park YD; Yasui M; Yoshimoto T; Chayama K; Shimono T; Okamura T; Inoue M; Yumura-Yagi K; Kawa-Ha K
    Bone Marrow Transplant; 1997 May; 19(9):915-20. PubMed ID: 9156266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
    Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein C, protein S and antithrombin III levels in the course of bone marrow and subsequent liver transplantation due to veno-occlusive disease.
    Salat C; Holler E; Göhring P; Poley S; Kolb HJ; Pihusch R; Reinhardt B; Krämling HJ; Haller M; Hiller E
    Eur J Med Res; 1996 Nov; 1(12):571-4. PubMed ID: 9438165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD.
    Remberger M; Ringden O; Markling L
    Bone Marrow Transplant; 1995 Jan; 15(1):99-104. PubMed ID: 7742764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver.
    Remberger M; Ringdén O
    Eur J Haematol; 1997 Oct; 59(4):254-62. PubMed ID: 9338624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study.
    Lee JH; Lee KH; Kim S; Lee JS; Kim WK; Park CJ; Chi HS; Kim SH
    Bone Marrow Transplant; 1998 Nov; 22(9):883-8. PubMed ID: 9827816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.
    Hasegawa S; Horibe K; Kawabe T; Kato K; Kojima S; Matsuyama T; Hirabayashi N
    Bone Marrow Transplant; 1998 Dec; 22(12):1191-7. PubMed ID: 9894723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation.
    Schots R; Kaufman L; Van Riet I; Ben Othman T; De Waele M; Van Camp B; Demanet C
    Leukemia; 2003 Jun; 17(6):1150-6. PubMed ID: 12764383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality.
    Schots R; Kaufman L; Van Riet I; Lacor P; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 1998 Jul; 22(1):79-85. PubMed ID: 9678800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
    Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
    Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A study on the relations of soluble interleukin-2 receptor and CD+25 cell with acute graft-versus-host disease].
    Ju X; Wang J; Zhang W; Song X; Zhou K; Gong S
    Zhonghua Nei Ke Za Zhi; 2001 Apr; 40(4):222-5. PubMed ID: 11798579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.